AU2007290960B2 - Anticancer use of caffeic acid and its derivatives - Google Patents

Anticancer use of caffeic acid and its derivatives Download PDF

Info

Publication number
AU2007290960B2
AU2007290960B2 AU2007290960A AU2007290960A AU2007290960B2 AU 2007290960 B2 AU2007290960 B2 AU 2007290960B2 AU 2007290960 A AU2007290960 A AU 2007290960A AU 2007290960 A AU2007290960 A AU 2007290960A AU 2007290960 B2 AU2007290960 B2 AU 2007290960B2
Authority
AU
Australia
Prior art keywords
phenyl
dihydroxy
propenone
abl
bcr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007290960A
Other languages
English (en)
Other versions
AU2007290960A1 (en
Inventor
Valmik Sopan Aware
Amit Deshpande
Kalpana Sanjay Joshi
Ankush Gangaram Sarde
Somesh Sharma
Meenakshi Sivakumar
Vilas Sampatrao Wagh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Piramal Enterprises Ltd
Original Assignee
Piramal Enterprises Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Enterprises Ltd filed Critical Piramal Enterprises Ltd
Publication of AU2007290960A1 publication Critical patent/AU2007290960A1/en
Assigned to Piramal Enterprises Limited reassignment Piramal Enterprises Limited Request for Assignment Assignors: PIRAMAL LIFE SCIENCES LIMITED
Application granted granted Critical
Publication of AU2007290960B2 publication Critical patent/AU2007290960B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2007290960A 2006-09-01 2007-08-20 Anticancer use of caffeic acid and its derivatives Ceased AU2007290960B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84206006P 2006-09-01 2006-09-01
US60/842,060 2006-09-01
PCT/IB2007/053308 WO2008026125A2 (en) 2006-09-01 2007-08-20 Anti cancer use of caffeic acid and derivatives

Publications (2)

Publication Number Publication Date
AU2007290960A1 AU2007290960A1 (en) 2008-03-06
AU2007290960B2 true AU2007290960B2 (en) 2013-04-18

Family

ID=39015871

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007290960A Ceased AU2007290960B2 (en) 2006-09-01 2007-08-20 Anticancer use of caffeic acid and its derivatives

Country Status (12)

Country Link
US (1) US20100010002A1 (cg-RX-API-DMAC7.html)
EP (1) EP2061452B1 (cg-RX-API-DMAC7.html)
JP (1) JP2010502586A (cg-RX-API-DMAC7.html)
AT (1) ATE530176T1 (cg-RX-API-DMAC7.html)
AU (1) AU2007290960B2 (cg-RX-API-DMAC7.html)
CA (1) CA2662126A1 (cg-RX-API-DMAC7.html)
DK (1) DK2061452T3 (cg-RX-API-DMAC7.html)
ES (1) ES2376277T3 (cg-RX-API-DMAC7.html)
IL (1) IL197262A0 (cg-RX-API-DMAC7.html)
PT (1) PT2061452E (cg-RX-API-DMAC7.html)
TW (1) TW200812955A (cg-RX-API-DMAC7.html)
WO (1) WO2008026125A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010052732A1 (en) * 2008-11-07 2010-05-14 Council Of Scientific & Industrial Research Cinnamido-pvrrolor[2,1-c][1,4]benzodiazepines as potential anticancer agents and process for the preparation thereof
CN101456890B (zh) * 2008-12-17 2011-02-02 中南大学 白血病bcr/abl融合基因mRNA的特异性抑制剂
BRPI1015124B8 (pt) 2009-05-04 2021-05-25 Prometic Biosciences Inc compostos aromáticos substituídos para a prevenção ou tratamento de distúrbios sanguíneos; distúrbios renais, nefropatias e/ou complicações do distúrbio renal; doenças relacionadas com inflamação; e distúrbios relacionados ao estresse oxidativo, usos farmacêuticos dos mesmos e composição farmacêutica comprendendo ditos compostos
WO2011104680A1 (en) * 2010-02-25 2011-09-01 Piramal Life Sciences Limited Oxadiazole compounds, their preparation and use
KR101821646B1 (ko) 2010-10-27 2018-01-25 프로메틱 파마 에스엠티 리미티드 암을 치료하기 위한 화합물 및 조성물
US20140127316A1 (en) * 2011-05-20 2014-05-08 New York University Propolis and caffeic acid phenethyl ester and uses thereof
WO2014190035A2 (en) * 2013-05-21 2014-11-27 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of cancer using histone h3k27me2 biomarkers and modulators
WO2017161093A1 (en) * 2016-03-17 2017-09-21 Musc Foundation For Research Development Caffeic acid derivatives and uses thereof
PH12022550608A1 (en) * 2019-09-17 2023-01-23 Enzene Biosciences Ltd Compositions for use in inhibiting src kinase and treating and preventing associated disorders
US11878971B2 (en) 2020-12-29 2024-01-23 Huscion Co., Ltd. Piperlongumine-based compound and immuno regulator comprising the same
EP4277896A4 (en) * 2021-01-14 2025-03-05 B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University COMPOUNDS FOR STIMULATING AGAINST GASTRIC BIOFILM AND REDUCE INFLAMMATION, COMPOSITIONS AND METHODS OF USE THEREOF

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040006138A1 (en) * 2002-07-08 2004-01-08 Council Of Scientific Pharmaceutical composition useful for treating chronic myeloid leukemia
WO2005099721A2 (en) * 2004-04-15 2005-10-27 The Regents Of The University Of California Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216024A (en) * 1987-07-28 1993-06-01 Baylor College Of Medicine Cell growth inhibitors and methods of treating cancer and cell proliferative diseases
US5008441A (en) * 1987-08-04 1991-04-16 The Trustees Of Columbia University In The City Of New York Caffeic acid esters and methods of producing and using same
JP4440767B2 (ja) * 2002-05-31 2010-03-24 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ 潜在的抗白血病薬としての薬草分子
WO2004004708A1 (en) * 2002-07-08 2004-01-15 Council Of Scientific And Industrial Research A pharmaceutical composition useful for treating chronic myeloid leukemia
US20050282892A1 (en) * 2002-07-08 2005-12-22 Santu Bandyopadhyay Pharmaceutical composition useful for treating chronic myeloid leukemia
US20070161704A1 (en) * 2002-07-08 2007-07-12 Council Of Scientific And Industrial Research Pharmaceutical composition useful for treating chronic myeloid leukemia
US20060045887A1 (en) 2004-08-25 2006-03-02 Gavish-Galilee Bio Applications Ltd. Mushroom extracts having anticancer activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040006138A1 (en) * 2002-07-08 2004-01-08 Council Of Scientific Pharmaceutical composition useful for treating chronic myeloid leukemia
WO2005099721A2 (en) * 2004-04-15 2005-10-27 The Regents Of The University Of California Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof

Also Published As

Publication number Publication date
ES2376277T3 (es) 2012-03-12
EP2061452B1 (en) 2011-10-26
DK2061452T3 (da) 2012-02-13
PT2061452E (pt) 2012-01-13
JP2010502586A (ja) 2010-01-28
IL197262A0 (en) 2009-12-24
EP2061452A2 (en) 2009-05-27
CA2662126A1 (en) 2008-03-06
WO2008026125A3 (en) 2008-10-02
US20100010002A1 (en) 2010-01-14
ATE530176T1 (de) 2011-11-15
TW200812955A (en) 2008-03-16
WO2008026125A2 (en) 2008-03-06
AU2007290960A1 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
AU2007290960B2 (en) Anticancer use of caffeic acid and its derivatives
JP2010502586A5 (cg-RX-API-DMAC7.html)
Yan et al. Targeting autophagy to sensitive glioma to temozolomide treatment
JP6626437B2 (ja) ヒストンデアセチラーゼ阻害剤とＨｅｒ２阻害剤またはＰＩ３Ｋ阻害剤のいずれかの組み合わせ
US20240343682A1 (en) Pcna inhibitors
WO2013116786A1 (en) Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer
EP2433636A1 (en) Treatment of Malignant Diseases
JP2019511554A (ja) 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ
CN114246864B (zh) Csf1r激酶抑制剂及其用途
AU2014318748B2 (en) Novel anthranilic amides and the use thereof
JP5289310B2 (ja) 微小管破壊剤及びそれを含有する癌細胞増殖抑制剤
KR20230004595A (ko) 유방암 치료제
US10272055B2 (en) Therapeutic compounds and methods
EP3043809B1 (en) Filipendula vulgaris extract and uses thereof
US20190290611A1 (en) Cis-gnetin h and trans-gnetin h as therapeutic agents
TWI434680B (zh) 二萜類化合物於治療攝護腺癌之用途
US20170340688A1 (en) Titrated extracts of cynara scolymus and uses thereof
EP1667719B1 (en) Treatment of gastrointestinal stromal tumors with imatinib and midostaurin
CN111905102A (zh) Ezh2抑制剂在治疗胶质瘤中的应用
US20230025625A1 (en) Radiation sensitivity enhancing comoposition containing aripiprazole as active ingredient
CA3028461A1 (en) Combination therapies for treating cancer
AU2024278807A1 (en) Mitochondria specific transcription inhibitors
US20170304223A1 (en) Method of treating prostate cancer using a pkc inhibitor
KR20240168426A (ko) 2-[(2-옥소-4-페닐-2h-크로멘-7-일)옥시]프로판아미도 유도체
KR20250102322A (ko) 삼중음성유방암 치료 및 예방용 약학조성물

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: PIRAMAL ENTERPRISES LIMITED

Free format text: FORMER APPLICANT(S): PIRAMAL LIFE SCIENCES LIMITED

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired